Join Palatin Technologies for a virtual KOL event featuring Jesse Richards, DO (Oklahoma State University College of Osteopathic Medicine), who will discuss the current treatment landscape for obesity, the need for new treatments with alternative mechanisms of action and how combining a melanocortin agonist with incretins can optimize treatment.

The event will focus on the Company’s metabolic program evaluating novel selective melanocortin-4 receptor (MCR4) agonists as a treatment for obesity in combination with a GLP-1 agonist. Palatin’s Phase 2 clinical study is targeted to start mid-calendar year 2024, with topline data readout expected by end of calendar year 2024.

A live question and answer session will follow the formal presentation.